Patent Law Weblog
recent posts
- Reasons for the PTAB’s Priority Determination in Broad’s Favor (Perhaps)
- Mexico Publishes Amendments to Intellectual Property Law
- PTAB (Again) Awards Priority of Invention to Broad in Interference No. 106,115
- Argentina Repeals Pharmaceutical Patent Examination Guidelines
- USPTO Moves to Protect Design Rights for Digital Innovations
about
Month: September 2007
-
By Donald Zuhn — On August 21, 2007, the U.S. Patent and Trademark Office published new rules concerning continuation and claims practice that will undoubtedly have a profound effect on the way patent attorneys and agents prosecute applications before the Patent Office. In view of the 128-page Federal Register notice regarding the new…
-
September 24-25, 2007 – Biosimilars 2007 (Scherago International, Inc.) – George Washington University, Washington, D.C. September 26-27, 2007 – Advanced Forum on Biotech Patents (American Conference Institute) – Boston, MA*** September 27-28, 2007 – Biotechnology: Business and Legal Developments (Law Seminars International) – Seattle, WA October 10-12, 2007 – Stem Cells European Business Summit –…
-
By Jason Derry — Exelixis and Bristol-Myers Squibb have announced an agreement to extend their research collaboration relating to cardiovascular and metabolic diseases for an additional year, now ending in January 2009. Under the terms of the extension, Exelixis will receive an additional $7.5 million in funding. The collaboration is focused on developing…
-
World Research Group (WRG) will be offering a webinar entitled: "New Patent Rules Update: Implications of Compliance" on October 16, 2007 from 12:00-1:30 PM (EST). Speakers Charles R. Macedo and Marlon P. Metelski of Amster, Rothstein and Ebenstein LLP will explain the new rule changes and their implications for patent practice. The registration fee for…
-
By Sherri Oslick — On Thursday, Celera of Rockville, MD and Alameda, CA, an Applera Corporation business, announced that it would acquire Atria Genetics, Inc. of San Fransisco, CA for approximately $33 million cash. Atria Genetics is a private company that has developed a line of human leukocyte antigen (HLA) testing products that…
-
By Donald Zuhn — Earlier this month, CODA Genomics, Inc. announced that it had been granted U.S. Patent No. 7,262,031. CODA Genomics, Inc., which derives its name from its Computational Optimized DNA Assembly technology, has exclusively licensed the ‘031 patent from the University of California, Irvine (UCI) Office of Technology Assessment (OTA). The…
-
Daiichi Sankyo Co. v. Apotex, Inc. (Fed. Cir. 2007) (reissued as precedential) By Robert Dailey — Much of patent law depends on the attributes of the hypothetical "person having ordinary skill in the art" (PHOSITA). Particularly, claim construction and obviousness determinations depend on how the court defines PHOSITA for the patent-in-suit. Nevertheless, Federal…
-
By Christopher P. Singer — In the Federal Register published Monday, September 10, 2007 (available here), the U.S. Patent and Trademark Office published its Final rules regarding certain changes the Office made in order to conform with changes introduced in the April 1, 2007 Revisions to the Patent Cooperation Treaty Procedures. As previously…
-
By Donald Zuhn — Earlier today, Patent Docs participated in a conference call with Jim Greenwood, the President and CEO of the Biotechnology Industry Organization (BIO). Mr. Greenwood, who represented Pennsylvania’s Eighth District in the U.S. House of Representatives from January 1993 through January 2005 prior to his BIO appointment, had invited a…
-
By Sherri Oslick — As reported here, on August 9, Eli Lilly filed suit in the District Court of New Jersey against Actavis Elizabeth in answer to Actavis’ filing of an ANDA (and concomitant Paragraph IV certification) to manufacture a generic version of Lilly’s Strattera®. Earlier this month, Lilly filed an amended complaint…
Patent Docs 